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1 
Introduction 
 The goal of this study was to synthesize 1-(6-(dimethylamino)naphthalen-2-yl)-2,2-
dimethylpropan-1-one, a PRODAN derivative, and perform fluorescence studies comparing the 
efficacy of various PRODAN derivatives as probes of solvent acidity in biological systems. 
These experiments involved allowing various PRODAN derivatives to bind to human serum 
albumin (HSA) and performing fluorescence titrations to determine relative quantum yields via 
integrated fluorescence intensities.  
 
Figure 1. Structure of 6-Propionyl-2-dimethylaminonaphthalene (PRODAN) 
6-Propionyl-2-dimethylaminonaphthalene (PRODAN), shown in Figure 1, is a 
fluorophore which can be modified to be structurally similar to cholesterol, shown in Figure 2. 
The PRODAN model of cholesterol that has been prepared in the Abelt lab is shown in Figure 3. 
This means that PRODAN might be capable of probing systems which are involved in 
cholesterol trafficking, such as cell membranes, lipoproteins, and HSA. 
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Figure 2. Structure of Cholesterol 
 
 
Figure 3. Structure of PRODAN Cholesterol Model 
Compound 1, 3-(dimethylamino)-8,9,10,11-tetrahydro-7H-cyclohepta[a] naphthalen -7-
one, shown in Figure 4, is similar to the parent PRODAN molecule, except it contains a 
somewhat bulky and relatively hydrophobic seven membered ring. The hydrophobic nature of 
the HSA cavity should allow for stronger binding with this other derivative, but the ability of the 
carbonyl to hydrogen bond with solvents may be limited due to its being constrained.  
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Figure 4. Structure of 3-(dimethylamino)-8,9,10,11-tetrahydro-7H-cyclohepta[a] 
naphthalen -7-one (Compound 1) 
 
Compound 2, 1-[6-(dimethylamino)-2-naphthalenyl]-2,2-dimethyl-1-propanone, 
contains a bulky t-butyl group, which may limit how far into the hydrophobic cavity that this 
derivative can penetrate. As a result, the carbonyl would more readily hydrogen bond to solvent, 
causing the probe to be highly sensitive to solvent acidity. 
 
Figure 5. Structure of 1-[6-(dimethylamino)-2-naphthalenyl]-2,2-dimethyl-1-
propanone (Compound 2) 
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Background 
Cholesterol is transported through the body between cells and the liver via lipoproteins 
such as HDL and LDL. This view is simplified in that it ignores the importance of HSA in 
transporting cholesterol from LDL to cells and from cells to HDL.1 The sheer abundance of HSA 
in the blood stream, 40mg/mL, makes it one of the most important transport proteins in the body. 
2
  It was been suggested that low levels of HSA may be a fair predictor of increased risk of death 
from coronary heart disease. 1 Aside from transporting cholesterol, HSA partakes in transporting 
a variety of important biological molecules, including other steroids, drugs, monoacylglycerols, 
and fatty acid chains. 1  
HSA is a monomeric protein containing three structurally-analogous α-helical domains, 
which in turn, each contain two subdomains composed of six or four helices, subdomains A and 
B respectively. 3 These subdomains each contain relatively hydrophobic pockets at which non-
polar molecules may bind via hydrophobic and electrostatic interactions. 3, 4 
 
Figure 6. Structure of Warfarin 
Warfarin binds fairly readily to HSA at subdomain IIA, with 99% forming a drug-HSA 
complex under “normal therapeutic conditions.” 3 PRODAN’s structural similarity to the drug 
Warfarin is important in that they are relatively hydrophobic molecules with electron density 
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concentrated at the center of the molecule.4  The comparable structures result in competitive 
binding to HSA. Studies done by Krishnakumar et al. indicate that binding up to three 
equilvalents of the fatty acid, palmitic acid, to HSA will increase the quantum yield of the 
PRODAN-HSA complex.6 However, further addition of palmitic acid will decrease the 
fluorescence quantum yields. This is attributed to the denaturation of HSA in a relatively acidic 
environment. The addition of fatty acids is believed to cause domains I and III to rotate resulting 
in an enhanced hydrophobic cavity at domain II.  
Interestingly, there are two enantiomers of Warfarin, which both bind to HSA similarly, 
indicating a lack of stereospecificity at the binding cavity. 3 The lack of specificity at the binding 
site permits binding of PRODAN derivatives similar in size, structure, and hydrophobicity, 
allowing for a larger range of acceptable models. Although probe models such as PRODAN are 
drastically different from cholesterol in terms of structure, they are capable of binding to HSA 
and are still capable of yielding information regarding HSA binding. For instance, studies done 
by Moreno et al. regarding HSA and PRODAN indicate a single equilibrium. 4 The importance 
of this finding is that there is primarily one HSA binding site that PRODAN will preferentially 
bind to: subdomain IIA.  
HSA, unlike a membrane, contains some specificity regarding orientation of PRODAN 
derivatives. 7 While membranes allow for an upside-down cholesterol orientation which can 
rotate to a rightside-up orientation, and vice versa, HSA will bind to PRODAN such that the 
polar features, such as the carbonyl group, will be found at the mouth of the binding cavity. 3, 7 
An important note about HSA is that it has a single tryptophan residue which emits at 
445nm when absorbing at 295nm. 4 Fortunately, this fluorescence of free HSA is quenched by 
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the addition of PRODAN. The absorption of PRODAN is far enough apart from HSA’s 
tryptophan residue’s absorption that we can selectively analyze PRODAN’s absorption. 
PRODAN is an amphiphilic molecule containing two rings, and like cholesterol, it is 
relatively hydrophobic. The carbonyl group is capable of accepting electrons and the alkylamino 
group is capable of donating electrons, which make PRODAN derivatives sensitive to their 
micropolarity and microacidity. 8  
The challenge is discerning the difference between solvent polarity and solvent acidity 
effects. Shifts in fluorescence peak maxima are a result of sensitivity to micropolarity of the 
probe’s environment. According to Park, Park, and Hamilton, a red shift is due to fluorescence of 
the probe after binding to the nonpolar cavity of HSA.9 Changes in maximum peak intensity are a 
result of changes in solvent acidity. 
Catalan developed a method of analyzing solvents by four characteristics: solvent 
dipolarity, solvent polarizability, solvent acidity, and solvent basicity.10 They determined that, of 
the four characteristics, solvent acidity has the greatest influence on the electronic transitions 
observed by the probes. Solvent acidity is the ability of the solvent to donate protons.  
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Experimental 
NMR specta were obtained using a Varian Mercury VX-400 spectrometer. Absorption 
and fluorescence emission measurements were obtained using an Ocean Optics HR2000 
spectrometer. Fluorescence excitations were done by an SLM-AMinco SPF-500 spectrometer. 
Solvents used for quantum yield determinations were spectrophotochemical grade from Acros.  
 
Synthesis of New Prodan Derivative 
1-[6-(dimethylamino)-2-naphthalenyl]-2,2-dimethyl-1-propanone. 6-Bromo-N,N-dimethyl-2-
naphthylamine (2.00g, 0.008mol) was dissolved in dry THF (30mL) under N2 and cooled to -
78°C. BuLi (5.3mL, 1.6M in hexanes) was added slowly dropwise and the reaction was left to 
stir for 30 minutes. 2,2-Dimethyl-1-(1H-pyrrol-1-yl)-1-propanone (1.13mL) was added dropwise 
and the reaction was left to stir for 1.5 hrs, allowing the temperature to rise to -40°C. The 
reaction was quenched with water (440mL) and left to stir overnight. NaCl (44.45g) was added 
to the quenched reaction. Acetic acid (44mL) was added to the reaction. The product was 
extracted with ether (2 x 150mL), then washed with water (2 x 74mL), and finally washed with a 
2% NaHCO3 solution (3 x 74mL). The product was dried over Na2SO4 and concentrated in 
vacuo. The crude product was purified with column chromatogrpahy. The fractions collected 
from the column were sublimed and recrystallized giving purified product (0.13g, 0.0005mol, 
6.4% yield).  1HNMR (CDCl3) δ 8.15 (d, J= 1.6 Hz, 1H), δ 7.73 (dd, J= 2.0, 1.6 Hz, 1H), δ 7.67 
(d, J= 9.0Hz, 1H), δ 7.53 (d, J= 9.0 Hz, 1H), δ 7.07 (dd, J= 2.7, 2.3 Hz, 1H), δ 6.78 (d, J= 2.7 Hz, 
1H), δ 3.0 (s, 6H), δ 1.35 (s, 9H); 13C NMR (CDCl3) δ207.65, 150.13, 136.75, 131.01, 130.63, 
129.91, 126.19, 125.21, 116.57, 105.54, 44.31, 40.77, 28.83.  
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Quantum Yield Determinations 
A 20mM phosophate buffer solution was made by dissolving 0.24g NaH2PO4·2H2O and 
0.35g NaHPO4 in 100mL H2O. A 100μM HSA stock solution was made by dissolving 0.17g of 
Sigma-Aldrich’s essentially fatty acid free HSA in 25mL of the 22mM phosphate buffer solution. 
A stock 2.1mM PRODAN solution was made by dissolving 5.1mg PRODAN in 10mL of MeOH. 
A stock 2.3mM solution of Compound 1 was made by dissolving 5.9mg in 10mL MeOH. A 
stock 2.6mM solution of Compound 2 was made by dissolving 6.6mg in 10mL of MeOH. 13 
test tubes were prepared for the quantum yield determination of each probe: 11 test tubes 
containing 1mL of 20mM phosphate buffer and a 50μM injection of probe, one test tube 
containing only 1mL of buffer solution,  and one containing 1mL of buffer solution and a 5μL 
injection of a the probe’s stock solution . The 50μM injections of stock solution were 25μL for 
PRODAN, 21.5μL for Compound 1, and 19.5μL for Compound 2. Injections of 0μM, 3μM, 
6μM, 9μM, 12μM, 15μM, 18μM, 21μM, 24μM, 27μM, and 30μM HSA were added to labeled 
test tubes and the tubes were left over 2 nights to equilibrate with the probe. 
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Results and Discussion 
 The synthesis of Compound 2 first involves the exchange of bromine with lithium. The 
aryl-lithium compound places most of the electron density on the aromatic carbon atoms since 
lithium is highly electropositive. This allows the electrophilic attack of the aryl ring to the 
carbonyl of 2,2-dimethyl-1-(1H-pyrrol-1-yl)-1-propanone. The pyrrole is the better leaving 
group since a pyrrole anion is more stable than tert-butyl anion. Using a pyrrole reduces the 
probability of dimerization to produce a highly polar byproduct.  However, dimerization was 
problematic in this synthesis due to excess of starting material with respect to the pyrrole 
compound.  
 
Figure 7. Schematic of Synthesis for Compound 2 
 
 
Figure 8. Structure of 1,1-bis(6-(dimethylamino)naphthalen-2-yl)-2,2-dimethylpropan-1-ol  
(Byproduct) 
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 The increase in quantum yields of probe-HSA complexes relative to free probe in water 
was determined via fluorescence titrations. The titrations were done by maintaining a constant 
probe concentration and increasing the concentration of HSA by about 3uM, initially ignoring 
dilution effects. Dilution effects were accounted for later in the analysis. A buffer solution was 
necessary instead of purely spectroscopic grade water to prevent denaturing of HSA. Plots of 
absorption and fluorescence data for each probe are shown in Figures 9-14. 
 
Figure 9. Titration of PRODAN with HSA (Absorption) 
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Figure 10. Titration of PRODAN with HSA (Fluorescence) 
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Figure 11. Titration of Compound 1 with HSA (Absorption) 
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Figure 12. Titration of Compound 1 with HSA (Fluorescence) 
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Figure 13. Titration of Compound 2 with HSA (Absorption) 
-0.1
-0.05
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
300 320 340 360 380 400 420 440 460
A
b
so
rb
a
n
ce
Wavelength (nm)
Probe + HSA (absorbance)
0uM
3uM
6uM
9uM
12uM
15uM
18uM
21uM
24uM
27uM
30uM
15 
 
 
 
Figure 14. Titration of Compound 2 with HSA (Fluorescence) 
 As the concentration of HSA was increased, the fluorescence peak exhibited a blue shift 
from about 530nm to 460nm for both PRODAN and Compound 1. This shift is indicative of 
probe-HSA bonding since HSA has a relatively nonpolar cavity. A red shift from about 430nm to 
460nm was observed for increased HSA concentration to Compound 2, indicative of probe 
aggregation. Aggregation resulted in less precise absorption values since the probe was not 
dissolved in buffer solution as PRODAN and Compound 1 had been.  
 The red shifts of PRODAN and Compound 1 were greater than the blue shift of 
Compound 2. This indicates that the polarity of the aggregate is similar to the polarity of the 
microenvironment in HSA. However, this also results in poorer absorption data.  
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 All three probes exhibited significant sensitivity to solvent acidity based on increases in 
fluorescence intensities. The integrated fluorescence intensities are related to an increase in 
relative quantum yield.  
 The relative quantum yields were calculated by first determining the fraction, f, of bound 
probe. This was done by using Equation 1 from Park, Park, and Hamilton.9  
   ∑   	
/      (1) 
 In this equation, [F-HSA] is the concentration of probe bound to HSA at site i. The 
assumption is made that PRODAN only binds to subdomain IIA.  [F]o is the initial concentration 
of probe. A second assumption made is that the concentration of free HSA is zero since the 
concentration of probe is so much greater than the concentration of HSA being added and the 
binding constant is relatively large. This results in essentially complete binding of HAS, meaning 
that the fraction of bound probe is dependent largely on dilution effects. The ratio of bound 
probe to free probe is then multiplied by the absorption and integrated fluorescence to yield 
adjusted absorption and adjusted fluorescence intensities of bound probe, as shown in Equation 2 
and Equation 3, respectively. 

  
      (2) 
  ∑         (3) 
 The change in adjusted absorbance and fluorescence was plotted against increasing initial 
HSA concentration, accounting for dilution effects, as shown in Figures 15-20. The best fit line 
was determined for each plot.  
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Figure 15. Change in Absorption of PRODAN + HSA vs. Concentration HSA 
 
 
Figure 16. Change in Integrated Fluorescence of PRODAN + HSA vs. Concentration HSA 
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Figure 17. Change in Absorption of Compound 1 + HSA vs. Concentration HSA
Figure 18. Change in Integrated Fluorescence of Compound 1 + HSA vs.
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Figure 19. Change in Absorption of Compound 2 + HSA vs. Concentration HSA 
 
 
 
Figure 20. Change in Integrated Fluorescence of Compound 2 + HSA vs. Concentration 
HSA 
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By definition, quantum yield is a measure of the ratio of photons emitted to photons 
absorbed. Relative quantum yields of probe
determined using Equation 4.  

/	
 and 
/	

relative increases in absorption and integrated fluorescence.  
Probe
PRODAN
Compound 1
Compound 2
Figure 21
The relative quantum yield can be used to determine solvent acidity using 
curve shown in Figure 22 which was developed in the Abelt lab
Figure 22. Relative Fluorescence of Probe with Changing Solvent Acidity
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 The Imax value falls out of the equation when solving for the acidity of an unknown 
solvent, as shown in Equation 6. Iwater is the fluorescence of probe in water. I 
log 2:/:;6  - log 2:/:#$%6= slope x (SAwater – SAHSA)   (6) 
 Equation 6 can be rearranged to yield Equation 7, the solvent acidity of an unknown, in 
this case the solvent acidity inside HSA. The solvent acidity of water, as reported by Catalan is 
1.062.10 
SAunknown = SAwater - 
/01
<=>?
<@ A)(
B
 = SAwater – 
C2 DEFE G6
B
   (7) 
Probe Solvent Acidity 
PRODAN 1.20 
Compound 1 0.81 
Compound 2 0.86 
Figure 23. Summary of Solvent Acidity in HSA by Probe 
 PRODAN is not nearly as accurate a probe of solvent acidity as the other two PRODAN 
derivatives, based on relative quantum yields since there is greater overlap of free probe and 
probe-HSA peak fluorescences. A decreased relative fluorescence of the free probe results in less 
overlap of free probe and probe-HSA fluorescence peaks. However, it is difficult to determine 
which of the derivatives is better since the absorption data for Compound 2 is not as precise as 
for the other probes due to aggregation.   
The t-butyl group on the synthesized probe allows for increased hydrogen bond accepting 
ability of the carbonyl relative to the strained carbonyl of Compound 1. However, steric strain 
of the bulky t-butyl group limits movement of the carbonyl at the mouth of the HSA binding 
cavity which decreases hydrogen bonding ability relative to PRODAN.   
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Conclusion 
 The synthesis of 1-[6-(dimethylamino)-2-naphthalenyl]-2,2-dimethyl-1-propanone has a 
relatively low yield of 6.4%. Despite using a pyrrole to add the t-butyl and carbonyl substituent, 
the majority of starting material dimerized to form a highly polar byproduct. Research in 
determining a better method of reducing dimerization would make the reaction much more 
efficient.  
 Compound 1, 3-(dimethylamino)-8,9,10,11-tetrahydro-7H-cyclohepta[a] naphthalen -7-
one, was the best probe for measuring solvent acidity since the fluorescence of the free probe 
was almost entirely quenched and there was great sensitivity in fluorescence due to hydrogen 
bonding effects. The formation of an aggregate of Compound 2 makes it a less practical probe 
of solvent acidity. The true acidity in HSA due to presence of water molecules is likely around 
0.81.  
 Cholesterol is a four ring system. To have a better understanding of cholesterol transport, 
it is best if the models also contain four rings. The next step for this research would be to develop 
a four ring PRODAN model of cholesterol for each of the probes and determine solvent acidity 
within HSA of the modified probe-HSA complex.  
 Another possible route of investigation would be to crystallize the probe-HSA complexes 
and determine exactly how the probe is interacting with HSA, and to what extent. This will give 
information regarding the availability of the carbonyl to hydrogen bond with solvent molecules 
trapped within the HSA molecule. It would also be important to determine a binding constant. 
 Lastly, it would be interesting to develop a computational model to understand the role of 
solvent particles within HSA and monitor how changes in microacidity within HSA affect the 
molecule’s ability to bind to and transport cholesterol.     
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Appendix A 
1HNMR and 13CNMR for  
1-[6-(dimethylamino)-2-naphthalenyl]-2,2-dimethyl-1-propanone 
24 
 
Figure A1. 1HNMR of 1-[6-(dimethylamino)-2-naphthalenyl]-2,2-dimethyl-1-propanone 
 
Figure A2. 13CNMR of 1-[6-(dimethylamino)-2-naphthalenyl]-2,2-dimethyl-1-propanone  
25 
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